ASH 2010 Lenalidomide in MDS with Karyotypes other than del 5q and Refractory to ESAs
 

http://ash.confex.com/ash/2010/webpr...aper27957.html

4002 Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs)

More than 40 % of the patients in this study became transfusion-independent.

"In lower-risk MDS, anemia is the main therapeutic challenge. ESAs can frequently correct anemia, but not all pts respond and median response duration to ESAs is only about 2 years. LEN yields RBC transfusion-independence (TI) in 65% of lower risk MDS with del(5q)] and about 25% of lower risk MDS without del 5q "

"31 consecutive lower-risk non-del(5q) MDS with anemia refractory to ESAs ( Erythropoiesis-Stimulating Agents) were treated with LEN through a compassionate program."

"LEN yielded RBC transfusion independence in more than 40% of the patients and was well-tolerated. Treatment-induced cytopenia (a possible side-effect, akita) was associated with fewer erythroid responses and shorter response duration."